PDE10

PDE10 Related Products (30):

By Type:	Pan (16) Selective (4)
By Effects:	Inhibitors (29) Antagonist (1)

Cat. No.	Product Name	Effect	Purity

HY-18252

Avanafil	Inhibitor	98.66%
Avanafil (TA-1790) is a potent and selective phosphodiesterase-5 (PDE-5) inhibitor with IC₅₀ values of 5.2 nM, 630 nM, 5700 nM, 6200 nM, 12000 nM, 27000 nM, 51000 nM and 53000 nM for PDE-5, PDE-6, PDE-4, PDE-10, PDE-8, PDE-7, PDE-2 and PDE-1, respectively. Avanafil activates NO/cGMP/PKG signaling-pathway to decrease loss in BMD, bone atrophy, and oxidative stress. Avanafil inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Avanafil can be used for the research of erectile dysfunction and osteoporosis.

HY-50098

Mardepodect	Inhibitor	99.04%
Mardepodect (PF-2545920) is a potent, orally active and selective PDE10A inhibitor with an IC₅₀ of 0.37 nM, with >1000-fold selectivity over other PDEs. Mardepodect can cross the blood-brain barrier.

HY-12472

Balipodect	Inhibitor	99.47%
Balipodect (TAK-063) is a highly potent, selective and orally active PDE10A inhibitor with IC₅₀ of 0.30 nM; >15000-fold selectivity over other PDEs.

HY-108618

BC11-38	Inhibitor	99.42%
BC11-38 is a potent, selective, and biologically active PDE11 inhibitor, with IC₅₀s of 0.28 µM and >100 µM for PDE11 and PDE1-10, respectively. BC11-38 elevates cAMP levels, PKA-mediated ATF-1 phosphorylation, and cortisol production in H295R cells.

HY-111371

PF-05180999	Inhibitor	99.97%
PF-05180999 (PF-999) is a phosphodiesterase 2A (PDE2A) inhibitor, with an IC₅₀ of 1.6 nM.

HY-170435

PDE5-IN-13	Inhibitor
PDE5-IN-13 inhibits phosphodiesterase 5 (PDE5A) with an IC₅₀ of 3 nM. PDE5-IN-13 is a potential candidate for the treatment of PAH (pulmonary arterial hypertension). PDE5-IN-13 has high selectivity for targets over PDE1, PDE2, PDE3, PDE4, PDE7, PDE8, PDE9, PDE10, and PDE11. PDE5-IN-13 has reasonable drug-like profiles.

HY-169963

PDE1-IN-8	Inhibitor
PDE1-IN-8 (Compound 3f) is the inhibitor for PDE1 with an IC₅₀ of 11 nM. PDE1-IN-8 inhibits cAMP and cGMP signaling pathway, inhibits the differentiation and proliferation of cells into myofibroblast, and exhibits anti-fibrotic efficacy in Bleomycin (HY-17565)-induced rat pulmonary fibrosis model.

HY-124392

AMG580	Antagonist
AMG580 is a selective PDE10A antagonist with subnanomolar affinity for rat, primate, and human PDE10A. AMG580 can be used for the research of noninvasive radiotracer.

HY-153093

MK-8189	Inhibitor	99.88%
MK-8189 is a potent, orally active and selective PDE10A inhibitor with a K_i value of 29 pM. MK-8189 can be used in research of schizophrenia.

HY-100530C

Sp-cAMPS sodium salt	Inhibitor	99.45%
Sp-cAMPS sodium salt, a cAMP analog, is potent activator of cAMP-dependent PKA I and PKA II. Sp-cAMPS sodium salt is also a potent, competitive phosphodiesterase (PDE3A) inhibitor with a K_i of 47.6 µM. Sp-cAMPS sodium salt binds the PDE10 GAF domain with an EC₅₀ of 40 μM.

HY-50098A

Mardepodect hydrochloride	Inhibitor	99.94%
Mardepodect hydrochloride (PF-2545920 hydrochloride) is a potent, orally active and selective PDE10A inhibitor with an IC₅₀ of 0.37 nM, with >1000-fold selectivity over other PDEs. Mardepodect hydrochloride can cross the blood-brain barrier.

HY-117604

THPP-1	Inhibitor	98.75%
THPP-1, a SGC chemical probe, is a potent and orally bioavailable phosphodiesterase 10A (PDE10A) inhibitor, with K_i values of 1 nM and 1.3 nM for human and rat PDE10A, respectively. THPP-1 has excellent pharmacokinetic properties in preclinical species.

HY-135848

N-Methylbenzamide	Inhibitor	99.93%
N-Methylbenzamide is a potent phosphodiesterase 10A (PDE10A) inhibitor. N-Methylbenzamide has anti-cancer activity.

HY-100530B

Sp-cAMPS	Inhibitor
Sp-cAMPS, a cAMP analog, is potent activator of cAMP-dependent PKA I and PKA II. Sp-cAMPS is also a potent, competitive phosphodiesterase (PDE3A) inhibitor with a K_i of 47.6 µM. Sp-cAMPS binds the PDE10 GAF domain with an EC₅₀ of 40 μM.

HY-18078

PQ-10	Inhibitor	99.77%
PQ-10 is a potent inhibitor of Phosphodiesterase 10A (PDE10A) with IC₅₀ andED₅₀ of 4.6 nM and 13 mg/kg, respectively. PQ-10 induces patterns of brain glucose metabolism which can be a potential translational biomarker. PQ-10 has the potential for researching psychiatric disorders like schizophrenia.

HY-131973

PDE10A-IN-2 hydrochloride	Inhibitor	98.43%
PDE10A-IN-2 hydrochloride is a potent, highly selective and orally active phosphodiesterase 10A (PDE10A) inhibitor with an IC₅₀ of 2.8 nM. PDE10A-IN-2 hydrochloride shows selectivity of >3500-fold against other PDE subtypes. PDE10A-IN-2 hydrochloride can be used for pulmonary arterial hypertension (PAH) research.

HY-U00427

PDE2/PDE10-IN-1	Inhibitor	99.88%
PDE2/PDE10-IN-1 is a phosphodiesterase 2 (PDE2) and PDE10 inhibitor with IC₅₀s of 29 and 480 nM, respectively.

HY-12813

PDE10-IN-1	Inhibitor	99.44%
PDE10-IN-1 is a potent PDE10-IN-1 inhibitor extracted from Patent WO 2013192273 A1, for treating CNS and metabolic disorders.

HY-120741

PF-04822163	Inhibitor
PF-04822163 is an orally active, selective, and blood-brain barrier permeable PDE1 inhibitor with IC₅₀ values of 2 nM, 2.4 nM, and 7 nM for PDE1A, PDE1B, and PDE1C respectively. PF-04822163 can be used in the research of attention deficit hyperactivity disorder or Parkinson's disease.

HY-18252A

Avanafil dibenzenesulfonate	Inhibitor
Avanafil (TA-1790) dibenzenesulfonate is a potent and selective phosphodiesterase-5 (PDE-5) inhibitor with IC₅₀ values of 5.2 nM, 630 nM, 5700 nM, 6200 nM, 12000 nM, 27000 nM, 51000 nM and 53000 nM for PDE-5, PDE-6, PDE-4, PDE-10, PDE-8, PDE-7, PDE-2 and PDE-1, respectively. Avanafil dibenzenesulfonate activates NO/cGMP/PKG signaling-pathway to decrease loss in BMD, bone atrophy, and oxidative stress. Avanafil dibenzenesulfonate inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Avanafil dibenzenesulfonate can be used for the research of erectile dysfunction and osteoporosis.

Name
Email *

	Sorry, but the email address you supplied was invalid.